Title	Overall Response Rate
Number of Patients Screened	21
Number of Patients Enrolled	21
Number of Patients Evaluable for Toxicity	21
Number of Patients Evaluated for Efficacy	17
Evaluation Method	RECIST version 1.1
Response Assessment CR	n = 0 (0%)
Response Assessment PR	n = 0 (0%)
Response Assessment SD	n = 5 (29%)
Response Assessment PD	n = 12 (71%)
(Median) Duration Assessments PFS	1.8 months; confidence interval, 1.1–4.9
(Median) Duration Assessments OS	3.0 months; confidence interval, 1.9–6.6
Outcome Notes
Overall response rate and progression‐free survival were assessed using RECIST criteria version 1.1. Subjects were assessed at baseline and approximately every 9 weeks (±4 days) from the first dose of palbociclib until documented progression or withdrawal from the study.